Diversicare Healthcare Services (DVCR) 10-Q/A 2 Nov 18 2018 Q3 Quarterly report (amended) Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Oct. 29, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	Diversicare Healthcare Services, Inc.
Entity Central Index Key	919,956
Document Type	10-Q/A
Document Period End Date	Sep. 30, 2018
Amendment Flag	true
Amendment Description	Updated exhibit listing and exhibit 10.1
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		6,518,013

INTERIM CONSOLIDATED BALANCE SH

INTERIM CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
CURRENT ASSETS:
Cash and cash equivalents	$ 3,293	$ 3,524
Receivables, less allowance for doubtful accounts of $14,235 at December 31, 2017	65,927	64,929
Other receivables	1,551	375
Prepaid expenses and other current assets	3,829	3,248
Income tax refundable	862	537
Current assets of discontinued operations	20	45
Total current assets	75,482	72,658
PROPERTY AND EQUIPMENT, at cost	137,430	147,549
Less accumulated depreciation and amortization	(83,956)	(78,345)
Property and equipment, net	53,474	69,204
OTHER ASSETS:
Deferred income taxes, net	15,891	15,154
Deferred lease and other costs, net	279	137
Acquired leasehold interest, net	6,403	6,691
Assets held for sale	13,299	0
Other noncurrent assets	7,503	3,725
Total other assets	43,375	25,707
Total assets	172,331	167,569
CURRENT LIABILITIES:
Current portion of long-term debt and capitalized lease obligations, net	12,576	13,065
Trade accounts payable	14,146	14,080
Current liabilities of discontinued operations	461	461
Accrued expenses:
Payroll and employee benefits	20,131	20,013
Self-insurance reserves, current portion	13,051	8,792
Other current liabilities	8,361	7,856
Total current liabilities	68,726	64,267
NONCURRENT LIABILITIES:
Long-term debt and capitalized lease obligations, less current portion and deferred financing costs, net	77,308	74,603
Self-insurance reserves, less current portion	16,301	13,458
Accrued litigation contingency	6,400	0
Other noncurrent liabilities	5,134	8,779
Total noncurrent liabilities	105,143	96,840
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS’ EQUITY (DEFICIT):
Common stock, authorized 20,000 shares, $.01 par value, 6,749 and 6,687 shares issued, and 6,517 and 6,455 shares outstanding, respectively	68	67
Treasury stock at cost, 232 shares of common stock	(2,500)	(2,500)
Paid-in capital	23,267	22,720
Accumulated deficit	(23,432)	(14,534)
Accumulated other comprehensive income	1,059	709
Total shareholders’ equity (deficit)	(1,538)	6,462
Total liabilities and shareholder's equity	$ 172,331	$ 167,569

INTERIM CONSOLIDATED BALANCE _2

INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Allowance for doubtful accounts receivable		$ 14,235
Common stock, shares authorized (shares)	20,000,000	20,000,000
Common stock, par value (dollars per share)	$ 0.01	$ 0.01
Common stock, shares issued (shares)	6,749,000	6,687,000
Common stock, shares outstanding (shares)	6,517,000	6,455,000
Treasury stock, shares (shares)	232,000	232,000

INTERIM CONSOLIDATED STATEMENTS

INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Statement [Abstract]
PATIENT REVENUES, net	$ 141,431	$ 146,377	$ 423,798	$ 430,427
EXPENSES:
Operating	113,799	118,104	337,517	341,937
Lease and rent expense	13,764	13,791	41,202	41,297
Professional liability	2,933	2,617	8,890	8,011
Litigation contingency expense (Note 6)	6,400	0	6,400	0
General and administrative	7,537	8,083	24,971	25,277
Depreciation and amortization	2,964	2,988	8,692	8,095
Lease termination receipts	0	(180)	0	(180)
Total expenses	147,397	145,403	427,672	424,437
OPERATING INCOME (LOSS)	(5,966)	974	(3,874)	5,990
OTHER INCOME (EXPENSE):
Gain on sale of investment in unconsolidated affiliate			308	733
Other income	36	0	115	0
Interest expense, net	(1,666)	(1,668)	(4,996)	(4,692)
Hurricane costs	0	(232)	0	(232)
Total other expense	(1,630)	(1,900)	(4,573)	(4,191)
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	(7,596)	(926)	(8,447)	1,799
BENEFIT FOR INCOME TAXES	207	345	670	(651)
LOSS FROM CONTINUING OPERATIONS	(7,389)	(581)	(7,777)	1,148
INCOME (LOSS) FROM DISCONTINUED OPERATIONS:
Operating loss, net	(8)	1	(34)	(42)
NET LOSS	$ (7,397)	$ (580)	$ (7,811)	$ 1,106
Per common share – basic
Continuing operations (in dollars per share)	$ (1.15)	$ (0.09)	$ (1.22)	$ 0.18
Discontinued operations (in dollars per share)	0	0	(0.01)	(0.01)
Net income (loss) per common share – basic (dollars per share)	(1.15)	(0.09)	(1.23)	0.17
Per common share – diluted
Continuing operations (in dollars per share)	(1.15)	(0.09)	(1.22)	0.18
Discontinued operations (in dollars per share)	0	0	(0.01)	(0.01)
Net income (loss) per common share – diluted (dollars per share)	(1.15)	(0.09)	(1.23)	0.17
COMMON STOCK DIVIDENDS DECLARED PER SHARE OF COMMON STOCK (dollars per share)	$ 0.055	$ 0.055	$ 0.165	$ 0.165
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic (shares)	6,400	6,294	6,362	6,274
Diluted (shares)	6,400	6,294	6,362	6,465

INTERIM CONSOLIDATED STATEMEN_2

INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Statement [Abstract]
Tax expense (benefit), effect on operating loss	$ 0	$ 1	$ (11)	$ (25)

INTERIM CONSOLIDATED STATEMEN_3

INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Statement of Comprehensive Income [Abstract]
NET LOSS	$ (7,397)	$ (580)	$ (7,811)	$ 1,106
OTHER COMPREHENSIVE INCOME:
Change in fair value of cash flow hedge, net of tax	46	203	501	603
Less: reclassification adjustment for amounts recognized in net income	0	(115)	(151)	(348)
Total other comprehensive income	46	88	350	255
COMPREHENSIVE LOSS	$ (7,351)	$ (492)	$ (7,461)	$ 1,361

INTERIM CONSOLIDATED STATEMEN_4

INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
NET LOSS	$ (7,811)	$ 1,106
Discontinued operations	(34)	(42)
Income (loss) from continuing operations	(7,777)	1,148
Adjustments to reconcile income (loss) from continuing operations to net cash provided by operating activities:
Depreciation and amortization	8,692	8,095
Provision for doubtful accounts	0	6,407
Deferred income tax provision (benefit)	(829)	52
Provision for self-insured professional liability, net of cash payments	2,224	(168)
Litigation contingency expense	6,400	0
Stock-based compensation	947	766
Gain on sale of unconsolidated affiliate	(308)	(733)
Provision for leases in excess of cash payments	(1,363)	(517)
Deferred bonus	0	700
Other	250	388
Changes in assets and liabilities affecting operating activities:
Receivables, net	(2,134)	(8,387)
Prepaid expenses and other assets	(2,379)	459
Trade accounts payable and accrued expenses	2,391	1,977
Net cash provided by continuing operations	6,114	10,187
Discontinued operations	(645)	(241)
Net cash provided by operating activities	5,469	9,946
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(5,964)	(8,638)
Property acquisitions	0	(8,750)
Proceeds from sale of unconsolidated affiliate	308	1,100
Net cash used in continuing operations	(5,656)	(16,288)
Discontinued operations	0	0
Net cash used in investing activities	(5,656)	(16,288)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of debt obligations	(15,330)	(24,381)
Proceeds from issuance of debt	17,203	31,574
Financing costs	(137)	(195)
Issuance and redemption of employee equity awards	(219)	(94)
Payment of common stock dividends	(1,053)	(1,038)
Payment for preferred stock restructuring	(508)	(492)
Net cash (used in) provided by financing activities	(44)	5,374
Discontinued operations	0	0
Net cash (used in) provided by financing activities	(44)	5,374
NET DECREASE IN CASH AND CASH EQUIVALENTS	(231)	(968)
CASH AND CASH EQUIVALENTS, beginning of period	3,524	4,263
CASH AND CASH EQUIVALENTS, end of period	3,293	3,295
SUPPLEMENTAL INFORMATION:
Cash payments of interest	4,511	3,989
Cash payments of income taxes	474	667
Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]
Acquisition of equipment through capital lease	$ 203	$ 507

BUSINESS

BUSINESS	9 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BUSINESS	BUSINESS Diversicare Healthcare Services, Inc. (together with its subsidiaries, “Diversicare” or the “Company”) provides long-term care services to nursing center patients in ten states, primarily in the Southeast, Midwest, and Southwest. The Company’s centers provide a range of health care services to their patients and residents that include nursing, personal care, and social services. Additionally, the Company’s nursing centers also offer a variety of comprehensive rehabilitation services, as well as nutritional support services. The Company's continuing operations include centers in Alabama, Florida, Indiana, Kansas, Kentucky, Mississippi, Missouri, Ohio, Tennessee, and Texas. As of September 30, 2018 , the Company’s continuing operations consist of 76 nursing centers with 8,456 licensed nursing beds. The Company owns 18 and leases 58 of its nursing centers. Our nursing centers range in size from 48 to 320 licensed nursing beds. The licensed nursing bed count does not include 497 licensed assisted and residential living beds.

CONSOLIDATION AND BASIS OF PRES

CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS	9 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS	CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS The interim consolidated financial statements include the operations and accounts of Diversicare Healthcare Services and its subsidiaries, all wholly-owned. All significant intercompany accounts and transactions have been eliminated in consolidation. The Company had one equity method investee, which was sold during the fourth quarter of 2016. The sale resulted in a $1,366 gain in the fourth quarter of 2016. Subsequently, the Company recognized additional gains of $308 and $733 for the nine -month periods ended September, 2018 and 2017, respectively, related to the liquidation of remaining assets affiliated with the partnership. All amounts subject to the liquidation of remaining assets affiliated with the partnership have been settled. The interim consolidated financial statements for the three and nine month periods ended September 30, 2018 and 2017 , included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company’s financial position at September 30, 2018 , and the results of operations for the three and nine month periods ended September 30, 2018 and 2017 , and cash flows for the nine month periods ended September 30, 2018 and 2017 . The Company’s balance sheet information at December 31, 2017 , was derived from its audited consolidated financial statements as of December 31, 2017 . Effective January 1, 2018, we adopted the requirements of Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers (Topic 606), as discussed in Notes 3 and 4 to the interim consolidated financial statements. All amounts and disclosures set forth in this Form 10-Q have been updated to comply with the new standard. The results of operations for the periods ended September 30, 2018 and 2017 are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 .

RECENT ACCOUNTING GUIDANCE

RECENT ACCOUNTING GUIDANCE	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
RECENT ACCOUNTING GUIDANCE	RECENT ACCOUNTING GUIDANCE Recent Accounting Standards Adopted by the Company In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. Topic 606 is effective for annual and interim reporting periods beginning after December 15, 2017. The Company adopted the requirements of this standard effective January 1, 2018. The Company elected to apply the modified retrospective approach with the cumulative transition effect recognized in beginning retained earnings as of the date of adoption. The impact of the implementation to the consolidated financial statements for periods subsequent to adoption is not material. See Note 4, "Revenue Recognition" for a discussion regarding revenue recognition under the new standard. In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The ASU was issued as part of the FASB Simplification Initiative and involves several aspects of accounting for share-based payment transactions, including the income tax consequences and classification on the statement of cash flows. We adopted this standard as of January 1, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230). The ASU provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The guidance addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. The ASU is effective for annual and interim periods beginning after December 15, 2017, which required the Company to adopt these provisions in the first quarter of fiscal 2018 using a retrospective approach. The adoption did not have a material impact on our financial position, results of operations or cash flows. In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which requires that the Statement of Cash Flows explain the changes during the period of cash and cash equivalents inclusive of amounts categorized as Restricted Cash. As a result, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for periods beginning after December 15, 2017, which required the Company to adopt these provisions in the first quarter of fiscal 2018. The adoption did not have a material impact on our financial position, results of operations or cash flows. In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805) - Clarifying the Definition of a Business, which provides guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The adoption is effective for annual and interim periods beginning after December 15, 2017. The Company will evaluate future acquisitions under this guidance, which may result in future acquisitions being accounted for as asset acquisitions. In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. The amended standard specifies the modification accounting applicable to any entity which changes the terms or conditions of a share-based payment award. The new guidance is effective for all entities after December 15, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows. Accounting Standards Recently Issued But Not Yet Adopted by the Company In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. For short term leases (those with a term of 12 months or less and that do not include a lessee purchase option that is reasonably certain to be exercised), a lessee is permitted to make an accounting election by asset class not to recognize lease assets and lease liabilities, which would generally result in lease expense being recognized on a straight-line basis over the lease term. The standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. In July 2018, the FASB issued ASU 2018-11, Leases - Targeted Improvements, which allows lessees and lessors to recognize and measure existing leases at the beginning of the period of adoption without modifying the comparative period financial statements (which therefore will remain under prior GAAP, Topic 840, Leases). The Company intends to use the optional expedient to reflect adoption in the period of adoption (which is January 1, 2019 for us) rather than the earliest period presented. For periods presented under Topic 842, extensive quantitative and qualitative disclosures will be required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The Company anticipates this standard will have a material impact on the consolidated financial position, primarily from nursing center operating leases. The Company has organized an implementation group of cross-functional departmental management to ensure the completeness of the lease information (specifically for new contracts entered into after the adoption date), analyze the appropriate classification of leases under the new standard, and develop new processes to execute, approve and classify new leases on an ongoing basis. The Company has also implemented software tools and processes to maintain lease information critical to applying the standard. The Company is in the process of cataloging its existing lease contracts and implementing changes to the systems, related processes and controls. The Company is planning to elect the package of practical expedients upon transition, which includes retaining the lease classification for any leases that exist prior to adoption of the standard. The Company is continuing to evaluate the extent of this anticipated impact on the consolidated financial position and results of operations and the quantitative and qualitative factors that will impact the Company as part of the adoption. The Company is additionally evaluating any modifications to its leasing strategy in response to the requirements of this standard. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for the fiscal year beginning after December 15, 2019 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the consolidated financial statements and related notes. In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which is intended to simplify and amend the application of hedge accounting to more clearly portray the economics of an entity’s risk management strategies in its financial statements. The new guidance will make more financial and nonfinancial hedging strategies eligible for hedge accounting and reduce complexity in fair value hedges of interest rate risk. The new guidance also changes how companies assess effectiveness and amends the presentation and disclosure requirements. The new guidance eliminates the requirement to separately measure and report hedge ineffectiveness and generally the entire change in the fair value of a hedging instrument will be required to be presented in the same income statement line as the hedged item. The new guidance also eases certain documentation and assessment requirements and modifies the accounting for components excluded from the assessment of hedge effectiveness. The new guidance is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within those years. Early adoption is permitted in any interim period or fiscal year before the effective date. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures. In February 2018, the FASB issued ASU No. 2018-02, Income Statement- Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The new guidance allows entities the option to reclassify stranded tax effects resulting from the Tax Cuts and Jobs Act from accumulated other comprehensive income (OCI) to retained earnings. The new guidance allows the option to apply the guidance retrospectively or in the period of adoption. The guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures. In March 2018, the FASB issued ASU No. 2018-05, Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 ("SAB No. 118"), which allowed SEC registrants to record provisional amounts in earnings for the year ended December 31, 2017 due to the complexities involved in accounting for the enactment of the Tax Cuts and Jobs Act. The Company recognized the estimated income tax effects of the Tax Cuts and Jobs Act in its 2017 Consolidated Financial Statements in accordance with SAB No. 118.

REVENUE RECOGNITION

REVENUE RECOGNITION	9 Months Ended
	Sep. 30, 2018
Revenue from Contract with Customer [Abstract]
REVENUE RECOGNITION	REVENUE RECOGNITION On January 1, 2018, the Company adopted Accounting Standards Codification ("ASC") 606 using the modified retrospective method for all contracts as of the date of adoption. The reported results for 2018 reflect the application of ASC 606 guidance while the reported results for 2017 were prepared under the guidance of ASC 605, Revenue Recognition (ASC 605), which is also referred to herein as "legacy GAAP". The adoption of ASC 606 represents a change in accounting principle that will more closely align revenue recognition with the delivery of the Company's services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. ASC 606 requires companies to exercise more judgment and recognize revenue in accordance with the standard's core principle by applying the following five steps: Step 1: Identify the contract with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. Performance obligations are promises made in a contract to transfer a distinct good or service to the customer. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company has concluded that the contracts with patients and residents represent a bundle of distinct services that are substantially the same, with the same pattern of transfer to the customer. Accordingly, the promise to provide quality care is accounted for as a single performance obligation. The Company performed analyses using the application of the portfolio approach as a practical expedient to group patient contracts with similar characteristics, such that revenue for a given portfolio would not be materially different than if it were evaluated on a contract-by-contract basis. These analyses incorporated consideration of reimbursements at varying rates from Medicaid, Medicare, Managed Care, Private Pay, Assisted Living, Hospice, and Veterans for services provided in each corresponding state. It was determined that the contracts are not materially different for the following groups: Medicaid, Medicare, Managed Care and Private Pay and other (Assisted Living, Hospice and Veterans). In order to determine the transaction price, the Company estimates the amount of variable consideration at the beginning of the contract using the expected value method. The estimates consider (i) payor type, (ii) historical payment trends, (iii) the maturity of the portfolio, and (iv) geographic payment trends throughout a class of similar payors. The Company typically enters into agreements with third-party payors that provide for payments at amounts different from the established charges. These arrangement terms provide for subsequent settlement and cash flows that may occur well after the service is provided. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. Changes in the Company's expectation of the amount it will receive from the patient or third-party payors will be recorded in revenue unless there is a specific event that suggests the patient or third-party payor no longer has the ability and intent to pay the amount due and, therefore, the changes in its estimate of variable consideration better represent an impairment, or bad debt. These estimates are re-assessed each reporting period, and any amounts allocated to a satisfied performance obligation are recognized as revenue or a reduction of revenue in the period in which the transaction price changes. The Company satisfies its performance obligation by providing quality of care services to its patients and residents on a daily basis until termination of the contract. The performance obligation is recognized on a time elapsed basis, by day, for which the services are provided. For these contracts, the Company has the right to consideration from the customer in an amount that directly corresponds with the value to the customer of the Company's performance to date. Therefore, the Company recognizes revenue based on the amount billable to the customer in accordance with the practical expedient in ASC 606-10-55-18. Additionally, because the Company applied ASC 606 using certain practical expedients, the Company elected not to disclose the aggregate amount of the transaction price for unsatisfied, or partially unsatisfied, performance obligations for all contracts with an original expected length of one year or less. The Company incurs costs related to patient/resident contracts, such as legal and advertising expenses. The contract costs are expensed as incurred. They are not expected to be recovered and are not chargeable to the patient/resident regardless of whether the contract is executed. Financial Statement Impact of Adopting ASC 606 The Company adopted ASC 606 using the modified retrospective method. The cumulative effect of applying the new guidance to all contracts with customers as of January 1, 2018 was not material to the interim consolidated financial statements. As a result of applying the modified retrospective method to adopt ASC 606, the following adjustments were made to our operating results: Three Months Ended September 30, 2018 As Reported Increase (Decrease) Balances as if the previous accounting guidance was in effect Patient Revenues, net $141,431 3,903 (a) $145,065 (269) (b) 3,634 Operating Expenses $113,799 3,903 (a) $117,702 Total Expenses $147,397 3,903 (a) $151,300 (a) Adjusts for the implicit price concession of bad debt expense. (b) Adjusts for the implementation of ASC 606. Nine Months Ended September 30, 2018 As Reported Increase (Decrease) Balances as if the previous accounting guidance was in effect Patient Revenues, net $423,798 11,155 (a) $434,066 (887) (b) 10,268 Operating Expenses $337,517 11,155 (a) $348,672 Total Expenses $427,672 11,155 (a) $438,827 (a) Adjusts for the implicit price concession of bad debt expense. (b) Adjusts for the implementation of ASC 606. As of September 30, 2018 As Reported Increase (Decrease) Balances as if the previous accounting guidance was in effect Accounts Receivable $65,927 (887) (a) $81,275 16,235 (b) 15,348 Accumulated Deficit $(23,432) 887 (a) $(22,829) (284) (c) 603 (a) Adjusts for the implementation of ASC 606. (b) Adjusts for a direct reduction of accounts receivable that would have been reflected as allowance for doubtful accounts in the consolidated balance sheet prior to the adoption of ASC 606. (c) Reflects the tax impact for the ASC 606 adjustment of $887 . Disaggregation of Revenue The following table summarizes revenue from contracts with customers by payor source for the periods presented (dollar amounts in thousands): Three Months Ended September 30, 2018 2018 2017(1) As reported As Adjusted to Legacy GAAP As reported Medicaid $ 68,929 48.7 % $ 78,200 53.9 % $ 77,027 52.6 % Medicare 26,997 19.1 % 34,933 24.1 % 36,449 24.9 % Managed Care 12,404 8.8 % 10,874 7.5 % 10,992 7.5 % Private Pay and other 33,101 23.4 % 21,058 14.5 % 21,909 15.0 % Total $ 141,431 100.0 % $ 145,065 100.0 % $ 146,377 100.0 % Nine Months Ended September 30, 2018 2018 2017(1) As reported As Adjusted to Legacy GAAP As reported Medicaid $ 198,418 46.8 % $ 226,631 52.2 % $ 223,410 51.9 % Medicare 84,611 20.0 % 109,150 25.1 % 113,360 26.3 % Managed Care 39,919 9.4 % 34,854 8.0 % 31,756 7.4 % Private Pay and other 100,850 23.8 % 63,431 14.7 % 61,901 14.4 % Total $ 423,798 100.0 % $ 434,066 100.0 % $ 430,427 100.0 % (1) As noted above, prior period amounts have not been adjusted under the application of the modified retrospective method.

LONG-TERM DEBT AND INTEREST RAT

LONG-TERM DEBT AND INTEREST RATE SWAP	9 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
LONG-TERM DEBT AND INTEREST RATE SWAP	LONG-TERM DEBT AND INTEREST RATE SWAP The Company has agreements with a syndicate of banks for a mortgage term loan ("Original Mortgage Loan") and the Company’s revolving credit agreement ("Original Revolver"). On February 26, 2016, the Company executed an Amended and Restated Credit Agreement (the "Credit Agreement") which modified the terms of the Original Mortgage Loan and the Original Revolver Agreements dated April 30, 2013. The Credit Agreement increased the Company's borrowing capacity to $100,000 allocated between a $72,500 Mortgage Loan ("Amended Mortgage Loan") and a $27,500 Revolver ("Amended Revolver"). The Amended Mortgage Loan consists of a $60,000 term loan facility and a $12,500 acquisition loan facility. Loan acquisition costs associated with the Amended Mortgage Loan and the Amended Revolver were capitalized in the amount of $2,162 and are being amortized over the five -year term of the agreements. Under the terms of the amended agreements, the syndicate of banks provided the Amended Mortgage Loan with an original principal balance of $72,500 with a five -year maturity through February 26, 2021, and a $27,500 Amended Revolver through February 26, 2021. The Amended Mortgage Loan has a term of five years, with principal and interest payable monthly based on a 25 -year amortization. Interest on the term and acquisition loan facilities is based on LIBOR plus 4.0% and 4.75% , respectively. A portion of the Amended Mortgage Loan is effectively fixed at 5.79% pursuant to an interest rate swap with an initial notional amount of $30,000 . The Amended Mortgage Loan balance was $72,150 as of September 30, 2018 , consisting of $63,150 on the term loan facility with an interest rate of 6.00% and $9,000 on the acquisition loan facility with an interest rate of 6.8% . The Amended Mortgage Loan is secured by eighteen owned nursing centers, related equipment and a lien on the accounts receivable of these centers. The Amended Mortgage Loan and the Amended Revolver are cross-collateralized and cross-defaulted. The Company’s Amended Revolver has an interest rate of LIBOR plus 4.0% and is secured by accounts receivable and is subject to limits on the maximum amount of loans that can be outstanding under the revolver based on borrowing base restrictions. Effective October 3, 2016, the Company entered into the Second Amendment ("Second Revolver Amendment") to amend the Amended Revolver. The Second Revolver Amendment increased the Amended Revolver capacity from the $27,500 in the Amended Revolver to $52,250 ; provided that the maximum revolving facility be reduced to $42,250 on August 1, 2017. Subsequently, on June 30, 2017, the Company executed a Fourth Amendment (the "Fourth Revolver Amendment") to amend the Amended Revolver, which modifies the capacity of the revolver to remain at $52,250 . On December 29, 2016, the Company executed a Third Amendment ("Third Revolver Amendment") to amend the Amended Revolver. The Third Amendment modified the terms of the Amended Revolving Agreement by increasing the Company’s letter of credit sublimit from $10,000 to $15,000 . Effective June 30, 2017, the Company entered into a Second Amendment ("Second Term Amendment") to amend the Amended Mortgage Loan. The Second Term Amendment amended the terms of the Amended Mortgage Loan Agreement by increasing the Company's term loan facility by $7,500 . Effective February 27, 2018, the Company executed a Fifth Amendment to the Amended Revolver and a Third Amendment to the Amended Mortgage Loan. Under the terms of the Amendments, the minimum fixed charge coverage ratio shall not be less than 1.01 to 1.00 as of March 31, 2018 and for each quarter thereafter. As of September 30, 2018 , the Company had $18,500 borrowings outstanding under the Amended Revolver compared to $16,000 outstanding as of December 31, 2017 . The interest rate related to the Amended Revolver was 6.00% as of September 30, 2018 . The outstanding borrowings on the revolver were used primarily to compensate for accumulated Medicaid and Medicare receivables at recently acquired facilities as these facilities proceed through the change in ownership process with Centers for Medicare & Medicaid Services (“CMS”). Also, borrowings on the revolver relate to the timing of cash flows and our operating activities. Annual fees for letters of credit issued under the Amended Revolver are 3.0% of the amount outstanding. The Company has eleven letters of credit with a total value of $13,714 outstanding as of September 30, 2018 . Considering the balance of eligible accounts receivable, the letters of credit, the amounts outstanding under the revolving credit facility and the maximum loan amount of $37,710 the balance available for borrowing under the Amended Revolver was $5,496 at September 30, 2018 . The Company’s debt agreements contain various financial covenants, the most restrictive of which relates to debt service coverage ratios. The Company is in compliance with all such covenants at September 30, 2018 . Interest Rate Swap Transaction As part of the debt agreements entered into in April 2013, the Company entered into an interest rate swap agreement with a member of the bank syndicate as the counterparty. The Company designated its interest rate swap as a cash flow hedge and the earnings component of the hedge, net of taxes, is reflected as a component of other comprehensive income (loss). In conjunction with the February 26, 2016 amendment to the Credit Agreement, the Company amended the terms of its interest rate swap. The interest rate swap agreement has the same effective date and maturity date as the Amended Mortgage Loan, and has an amortizing notional amount that was $27,915 as of September 30, 2018 . The interest rate swap agreement requires the Company to make fixed rate payments to the bank calculated on the applicable notional amount at an annual fixed rate of 5.79% while the bank is obligated to make payments to the Company based on LIBOR on the same notional amount. The Company assesses the effectiveness of its interest rate swap on a quarterly basis, and at September 30, 2018 , the Company determined that the interest rate swap was highly effective. The interest rate swap valuation model indicated a net asset of $661 at September 30, 2018 . The fair value of the interest rate swap is included in “other noncurrent assets” on the Company’s interim consolidated balance sheet. The asset related to the change in the interest rate swap included in accumulated other comprehensive income at September 30, 2018 is $403 net of the income tax provision of $258 . As the Company’s interest rate swap is not traded on a market exchange, the fair value is determined using a valuation based on a discounted cash flow analysis. This analysis reflects the contractual terms of the interest rate swap agreement and uses observable market-based inputs, including estimated future LIBOR interest rates. The interest rate swap valuation is classified in Level 2 of the fair value hierarchy, in accordance with the FASB guidance set forth in ASC 820, Fair Value Measurement .

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2018
Health Care Organizations [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Professional Liability and Other Liability Insurance The Company has professional liability insurance coverage for its nursing centers that, based on historical claims experience, is likely to be substantially less than the claims that are expected to be incurred. Effective July 1, 2013, the Company established a wholly-owned, offshore limited purpose insurance subsidiary, SHC Risk Carriers, Inc. (“SHC”), to replace some of the expiring commercial policies. SHC covers losses up to specified limits per occurrence. All of the Company's nursing centers in Florida, and Tennessee are now covered under the captive insurance policies along with many of the nursing centers in Alabama, Kentucky, and Texas. The insurance coverage provided for these centers under the SHC policy provides coverage limits of at least $500 per medical incident with a sublimit per center of $1,000 and total annual aggregate policy limits of $5,000 . All other centers within the Company's portfolio are covered through various commercial insurance policies which provide similar coverage limits per medical incident, per location, and on an aggregate basis for covered centers. The deductibles for these policies are covered through the insurance subsidiary. Reserve for Estimated Self-Insured Professional Liability Claims Because the Company’s actual liability for existing and anticipated professional liability and general liability claims will likely exceed the Company’s limited insurance coverage, the Company has recorded total liabilities for reported and estimated future claims of $27,070 as of September 30, 2018 . This accrual includes estimates of liability for incurred but not reported claims, estimates of liability for reported but unresolved claims, actual liabilities related to settlements, including settlements to be paid over time, and estimates of legal costs related to these claims. All losses are projected on an undiscounted basis and are presented without regard to any potential insurance recoveries. Amounts are added to the accrual for estimates of anticipated liability for claims incurred during each period, and amounts are deducted from the accrual for settlements paid on existing claims during each period. The Company evaluates the adequacy of this liability on a quarterly basis. Semi-annually, the Company retains a third-party actuarial firm to assist in the evaluation of this reserve. Since May 2012, Merlinos & Associates, Inc. (“Merlinos”) has assisted management in the preparation of the appropriate accrual for incurred but not reported general and professional liability claims based on data furnished as of May 31 and November 30 of each year. Merlinos primarily utilizes historical data regarding the frequency and cost of the Company's past claims over a multi-year period, industry data and information regarding the number of occupied beds to develop its estimates of the Company's ultimate professional liability cost for current periods. On a quarterly basis, the Company obtains reports of asserted claims and lawsuits incurred. These reports, which are provided by the Company’s insurers and a third-party claims administrator, contain information relevant to the actual expense already incurred with each claim as well as the third-party administrator’s estimate of the anticipated total cost of the claim. This information is reviewed by the Company quarterly and provided to the actuary semi-annually. Based on the Company’s evaluation of the actual claim information obtained, the semi-annual estimates received from the third-party actuary, the amounts paid and committed for settlements of claims and on estimates regarding the number and cost of additional claims anticipated in the future, the reserve estimate for a particular period may be revised upward or downward on a quarterly basis. Any increase in the accrual decreases results of operations in the period and any reduction in the accrual increases results of operations during the period. As of September 30, 2018 , the Company is engaged in 83 professional liability lawsuits. Twenty lawsuits are currently scheduled for trial or arbitration during the next twelve months, and it is expected that additional cases will be set for trial or hearing. The Company’s cash expenditures for self-insured professional liability costs from continuing operations were $4,452 and $6,077 for the nine months ended September 30, 2018 and 2017 , respectively. The Company follows the FASB ASU No. 2010-24, "Presentation of Insurance Claims and Related Insurance Recoveries," that clarifies that a health care entity should not net insurance recoveries against a related professional liability claim and that the amount of the claim liability should be determined without consideration of insurance recoveries. Accordingly, the estimated insurance recovery receivables are included within "Other Current Assets" and "Other Noncurrent Assets" on the Consolidated Balance Sheet. As of September 30, 2018 there are estimated insurance recovery receivables of $5,425 . Although the Company adjusts its accrual for professional and general liability claims on a quarterly basis and retains a third-party actuarial firm semi-annually to assist management in estimating the appropriate accrual, professional and general liability claims are inherently uncertain, and the liability associated with anticipated claims is very difficult to estimate. Professional liability cases have a long cycle from the date of an incident to the date a case is resolved, and final determination of the Company’s actual liability for claims incurred in any given period is a process that takes years. As a result, the Company’s actual liabilities may vary significantly from the accrual, and the amount of the accrual has and may continue to fluctuate by a material amount in any given period. Each change in the amount of this accrual will directly affect the Company’s reported earnings and financial position for the period in which the change in accrual is made. Civil Investigative Demand ("CID") In July 2013, the Company learned that the United States Attorney for the Middle District of Tennessee ("DOJ") had commenced a civil investigation of potential violations of the False Claims Act ("FCA"). In October 2014, the Company learned that the investigation was started by the filing under seal of a false claims action against the two centers that were subject of the original civil investigative demand ("CID"). In connection with this matter, between July 2013 and early February 2016, the Company received three civil investigative demands (a form of subpoena) for documents. The Company has responded to those demands and also provided voluntarily additional information requested by the DOJ. The DOJ has also taken testimony from current and former employees of the Company. In May 2018, the Company learned that a second FCA complaint had been filed in late 2016 relating to the Company’s practices and policies for rehabilitation therapy at some of its facilities. The government’s investigation relates to the Company’s practices and policies for rehabilitation and other services at all of its facilities, for preadmission evaluation forms ("PAEs") required by TennCare and for Pre-Admission Screening and Resident Reviews ("PASRRs") required by the Medicare program. The Company is engaged in preliminary discussions with the DOJ regarding settlement of this investigation. The Company denies any wrong doing and is prepared to vigorously defend its actions. However, based upon preliminary settlement discussions, the Company believes that it is probable a loss will result from this contingency and has accrued $6,400 as a contingent liability in connection with this matter during the three months ended September 30, 2018. The Company cannot predict whether a settlement can be achieved, the outcome of the litigation if there is no settlement or the length of time necessary to conclude. Accordingly, the contingent liability has been classified as a noncurrent liability in the accompanying interim consolidated balance sheets. The Company’s ultimate ability to settle this investigation will depend on several factors, including whether the amount and terms of an acceptable settlement can be reached with the DOJ, the Company’s assessment of the risks of litigating this case and the effect of protracted litigation or settlement terms on the Company’s business plans. Because the outcome of this investigation and related settlement discussions remain uncertain, there is a reasonable possibility that the amount ultimately incurred in connection with the resolution of this matter could differ materially from the current accrual, as the Company cannot, at this time, estimate the possible range of loss that may result from either a settlement or litigation of this matter. The ultimate outcome of this litigation could have a materially adverse effect on the Company, including the imposition of treble damages, criminal charges, fines, penalties and/or a corporate integrity agreement. In June 2016, the Company received an authorized investigative demand (a form of subpoena) for documents in connection with a criminal investigation by the DOJ related to the practices of some of its employees with respect to PAEs and PASRRs, and the Company provided documents responsive to this subpoena and coordinated examinations of certain employees of the Company. The Company understands that this criminal investigation has been closed, subject to re-opening at the discretion of the government. Other Insurance With respect to workers’ compensation insurance, substantially all of the Company’s employees became covered under either a prefunded deductible policy or state-sponsored programs. The Company has been and remains a non-subscriber to the Texas workers’ compensation system and is, therefore, completely self-insured for employee injuries with respect to its Texas operations. From June 30, 2003 until June 30, 2007, the Company’s workers’ compensation insurance programs provided coverage for claims incurred with premium adjustments depending on incurred losses. From the period from July 1, 2008 through September 30, 2018 , the Company is covered by a prefunded deductible policy. Under this policy, the Company is self-insured for the first $500 per claim, subject to an aggregate maximum of $3,000 . The Company funds a loss fund account with the insurer to pay for claims below the deductible. The Company accounts for premium expense under this policy based on its estimate of the level of claims subject to the policy deductibles expected to be incurred. The liability for workers’ compensation claims is $620 at September 30, 2018 . The Company has a non-current receivable for workers’ compensation policies covering previous years of $1,074 as of September 30, 2018 . The non-current receivable is a function of payments paid to the Company’s insurance carrier in excess of the estimated level of claims expected to be incurred. As of September 30, 2018 , the Company is self-insured for health insurance benefits for certain employees and dependents for amounts up to $200 per individual annually. The Company provides reserves for the settlement of outstanding self-insured health claims at amounts believed to be adequate. The liability for reported claims and estimates for incurred but unreported claims is $1,662 at September 30, 2018 . The differences between actual settlements and reserves are included in expense in the period finalized.

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	9 Months Ended
	Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION Overview of Plans In June 2008, the Company adopted the Advocat Inc. 2008 Stock Purchase Plan for Key Personnel (“Stock Purchase Plan”). The Stock Purchase Plan provides for the granting of rights to purchase shares of the Company's common stock to directors and officers. The Stock Purchase Plan allows participants to elect to utilize a specified portion of base salary, annual cash bonus, or director compensation to purchase restricted shares or restricted share units (“RSU's”) at 85% of the quoted market price of a share of the Company's common stock on the date of purchase. The restriction period under the Stock Purchase Plan is generally two years from the date of purchase and during which the shares will have the rights to receive dividends, however, the restricted share certificates will not be delivered to the shareholder and the shares cannot be sold, assigned or disposed of during the restriction period. In June 2016, our shareholders approved an amendment to the Stock Purchase Plan to increase the number of shares of our common stock authorized under the Plan from 150 shares to 350 shares. No grants can be made under the Stock Purchase Plan after April 25, 2028. In April 2010, the Compensation Committee of the Board of Directors adopted the 2010 Long-Term Incentive Plan (“2010 Plan”), followed by approval by the Company's shareholders in June 2010. The 2010 Plan allows the Company to issue stock appreciation rights, stock options and other share and cash based awards. In June 2017, our shareholders approved an amendment to the 2010 Plan to increase the number of shares of our common stock authorized under the 2010 Plan from 380 shares to 680 shares. No grants can be made under the 2010 Plan after May 31, 2027. Equity Grants and Valuations During the nine months ended September 30, 2018 and 2017 , the Compensation Committee of the Board of Directors approved grants totaling approximately 90 and 88 shares of restricted common stock to certain employees and members of the Board of Directors, respectively. The fair value of restricted shares is determined as the quoted market price of the underlying common shares at the date of the grant. The restricted shares typically vest 33% on the first, second and third anniversaries of the grant date. Generally, unvested shares may not be sold or transferred. During the vesting period, dividends accrue on the restricted shares, but are paid in additional shares of common stock upon vesting, subject to the vesting provisions of the underlying restricted shares. The restricted shares are entitled to the same voting rights as other common shares. Upon vesting, all restrictions are removed. In addition, during the nine months ended September 30, 2018, the Company granted stock options to purchase a total of 30 shares of common stock at an exercise price equal to the market price of the Company’s common stock on the date of grant to two new directors. These stock options vest one third on the date of grant and one third on the first and second anniversary of the date of grant. Prior to 2017 , the Compensation Committee of the Board of Directors also approved grants of Stock Only Stock Appreciation Rights (“SOSARs”) and Stock Options at the market price of the Company's common stock on the grant date. The SOSARs and Options vest 33% on the first, second and third anniversaries of the grant date, and expire 10 years from the grant date. In computing the fair value estimates using the Black-Scholes-Merton valuation method, the Company took into consideration the exercise price of the equity grants and the market price of the Company's stock on the date of grant. The Company used an expected volatility that equals the historical volatility over the most recent period equal to the expected life of the equity grants. The risk free interest rate is based on the U.S. treasury yield curve in effect at the time of grant. The Company used the expected dividend yield at the date of grant, reflecting the level of annual cash dividends currently being paid on its common stock. Summarized activity of the equity compensation plans is presented below: Weighted Options/ Average SOSARs Exercise Price Outstanding, December 31, 2017 211 $ 6.64 Granted 30 8.14 Exercised (100 ) 5.79 Expired or cancelled (17 ) 9.76 Outstanding, September 30, 2018 124 $ 7.24 Exercisable, September 30, 2018 104 $ 7.06 Weighted Average Restricted Grant Date Shares Fair Value Outstanding, December 31, 2017 164 $ 9.95 Granted 90 8.14 Dividend Equivalents 4 6.95 Vested (131 ) 9.71 Cancelled (7 ) 9.62 Outstanding, September 30, 2018 120 $ 8.77 Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows: Weighted Average Restricted Grant Date Share Units Fair Value Outstanding, December 31, 2017 44 $ 9.59 Granted 16 8.14 Dividend Equivalents 1 6.89 Vested (17 ) 8.91 Outstanding, September 30, 2018 44 $ 9.25 The SOSARs and Options were valued and recorded in the same manner, and, other than amounts that may be settled pursuant to employment agreements with certain members of management, will be settled with issuance of new stock for the difference between the market price on the date of exercise and the exercise price. The Company estimated the total recognized and unrecognized compensation related to SOSARs and stock options using the Black-Scholes-Merton equity grant valuation model. The following table summarizes information regarding stock options and SOSAR grants outstanding as of September 30, 2018 : Weighted Average Intrinsic Intrinsic Range of Exercise Grants Value-Grants Grants Value-Grants Exercise Prices Prices Outstanding Outstanding Exercisable Exercisable $8.14 to $10.80 $ 9.32 60 $ — 40 $ — $2.37 to $5.86 $ 5.28 64 $ 75 64 $ 75 124 104 Stock-based compensation expense is non-cash and is included as a component of general and administrative expense or operating expense based upon the classification of cash compensation paid to the related employees. The Company recorded total stock-based compensation expense of $947 and $766 in the nine month periods ended September 30, 2018 and 2017 , respectively. The stock-based compensation expense balance for the nine month period ended September 30, 2018 is inclusive of $259 related to the vesting of executive equity awards.

EARNINGS PER COMMON SHARE

EARNINGS PER COMMON SHARE	9 Months Ended
	Sep. 30, 2018
Earnings Per Share [Abstract]
EARNINGS PER COMMON SHARE	EARNINGS PER COMMON SHARE Information with respect to basic and diluted net income (loss) per common share is presented below in thousands, except per share: Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Net loss Income (loss) from continuing operations $ (7,389 ) $ (581 ) $ (7,777 ) $ 1,148 Income (loss) from discontinued operations, net of income taxes (8 ) 1 (34 ) (42 ) Net loss $ (7,397 ) $ (580 ) $ (7,811 ) $ 1,106 Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Net income (loss) per common share: Per common share – basic Income (loss) from continuing operations $ (1.15 ) $ (0.09 ) $ (1.22 ) $ 0.18 Loss from discontinued operations — — (0.01 ) (0.01 ) Net income (loss) per common share – basic $ (1.15 ) $ (0.09 ) $ (1.23 ) $ 0.17 Per common share – diluted Income (loss) from continuing operations $ (1.15 ) $ (0.09 ) $ (1.22 ) $ 0.18 Loss from discontinued operations — — (0.01 ) (0.01 ) Net income (loss) per common share – diluted $ (1.15 ) $ (0.09 ) $ (1.23 ) $ 0.17 Weighted Average Common Shares Outstanding: Basic 6,400 6,294 6,362 6,274 Diluted 6,400 6,294 6,362 6,465 The effects of 124 and 46 SOSARs and options outstanding were excluded from the computation of diluted earnings per common share in the nine months ended September 30, 2018 and 2017 , respectively, because these securities would have been anti-dilutive.

BUSINESS DEVELOPMENTS AND OTHER

BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS	9 Months Ended
	Sep. 30, 2018
Business Combinations [Abstract]
BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS	BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS 2017 Acquisition During the year ended December 31, 2017, the Company expanded its operations to acquire a center that complements its current portfolio. On June 8, 2017, the Company entered into an Asset Purchase Agreement (the "Purchase Agreement") with Park Place Nursing and Rehabilitation Center, LLC, Dunn Nursing Home, Inc., Wood Properties of Selma LLC, and Homewood of Selma, LLC to acquire a 103 -bed skilled nursing center in Selma, Alabama, for an aggregate purchase price of $8,750 . The acquisition transaction closed on July 1, 2017. In accordance with ASC 805, this transaction was accounted for as a business combination, which resulted in the expensing of $ 140 of acquisition costs and a $ 925 recorded gain on bargain purchase for the Company for the year ended December 31, 2017. The operating results of the acquired center have been included in the Company's consolidated statement of operations since the acquisition date. Supplemental pro forma information regarding the acquisition is not material to the consolidated financial statements. The final allocation of the purchase price to the net assets acquired is as follows: Park Place Purchase Price $ 8,750 Gain on bargain purchase 925 $ 9,675 Allocation: Building $ 8,435 Land 760 Land Improvements 145 Furniture, Fixtures and Equipment 335 $ 9,675 2018 Assets Held for Sale During the first quarter of 2018, three of the Company's skilled nursing facilities met the accounting criteria to be classified as held for sale, but did not meet the accounting criteria to be reported as discontinued operations. The Company is selling the property and equipment affiliated with these centers. The carrying value of these centers' assets are $ 13,299 . The centers' assets are classified as held for sale in the accompanying interim consolidated balance sheets. Refer to Note 10 for further discussion. 2017 Lease Termination On September 30, 2017, the Company entered into an Agreement with Trend Health and Rehab of Carthage, LLC ("Trend Health") to terminate the lease and the Company's right of possession of the center in Carthage, Mississippi. In consideration of the early termination of the lease, Trend Health provided the Company with a $250 cash termination payment which is included in lease termination receipts in the accompanying interim consolidated statements of operations for the year ended December 31, 2017. For accounting purposes, this transaction was not reported as a discontinued operation as this disposal did not represent a strategic shift that has (or will have) a major effect on the Company's operations and financial results. 2016 Sale of Investment in Unconsolidated Affiliate On October 28, 2016, the Company and its partners entered into an asset purchase agreement to sell the pharmacy joint venture. The sale resulted in a $1,366 gain in the fourth quarter of 2016. Subsequently, the Company recognized additional gains of $308 and $733 for the nine -month periods ended September 30, 2018 and 2017, respectively, related to the liquidation of remaining assets affiliated with the partnership.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2018
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS On July 8, 2018, the Company entered into a membership interest purchase agreement with ALS Ontario Operating, Inc. to transfer all of the issued and outstanding membership units of Ontario Pointe, a stand-alone 50 bed assisted living facility. The termination of this lease was effective on October 1, 2018. On October 1, 2018, the Company entered into a New Master Lease Agreement (the "Lease") with Omega Healthcare Investors (the "Lessor") to lease 34 centers currently owned by Omega and operated by Diversicare. The old Master Lease with Omega provided for its operation of 23 skilled nursing centers in Texas, Kentucky, Alabama, Tennessee, Florida, and Ohio. Additionally, Diversicare operates 11 centers owned by Omega under separate leases in Missouri, Kentucky, Indiana, and Ohio. The Lease entered into by Diversicare and Omega consolidates the leases for all 34 centers under one New Master Lease. The Lease has an initial term of twelve years with two 10 year extensions. The Lease has a common date of annual lease fixed escalators of 2.15% beginning on October 1, 2019. On October 30, 2018, the Company entered into an Asset Purchase Agreement (the "Agreement") with Fulton Nursing and Rehabilitation LLC, Holiday Fulton Propco LLC, Birchwood Nursing and Rehabilitation LLC, Padgett Clinton Propco LLC, Westwood Nursing and Rehabilitation LLC, and Westwood Glasgow Propco (the "Buyers") to sell the assets and transfer the operations of Diversicare of Fulton, Diversicare of Clinton and Diversicare of Glasgow (the "Properties"). The purchase price of the Properties is $18,700 and the sale is expected to be completed in the fourth quarter of 2018.

CONSOLIDATION AND BASIS OF PR_2

CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Policies)	9 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Consolidation	The interim consolidated financial statements include the operations and accounts of Diversicare Healthcare Services and its subsidiaries, all wholly-owned. All significant intercompany accounts and transactions have been eliminated in consolidation.
Basis of Accounting	The interim consolidated financial statements for the three and nine month periods ended September 30, 2018 and 2017 , included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management of the Company, the accompanying interim consolidated financial statements reflect all normal, recurring adjustments necessary to present fairly the Company’s financial position at September 30, 2018 , and the results of operations for the three and nine month periods ended September 30, 2018 and 2017 , and cash flows for the nine month periods ended September 30, 2018 and 2017 . The Company’s balance sheet information at December 31, 2017 , was derived from its audited consolidated financial statements as of December 31, 2017 . Effective January 1, 2018, we adopted the requirements of Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers (Topic 606), as discussed in Notes 3 and 4 to the interim consolidated financial statements. All amounts and disclosures set forth in this Form 10-Q have been updated to comply with the new standard. The results of operations for the periods ended September 30, 2018 and 2017 are not necessarily indicative of the operating results that may be expected for a full year. These interim consolidated financial statements should be read in connection with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 .
Recent Accounting Guidance	Recent Accounting Standards Adopted by the Company In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. Topic 606 is effective for annual and interim reporting periods beginning after December 15, 2017. The Company adopted the requirements of this standard effective January 1, 2018. The Company elected to apply the modified retrospective approach with the cumulative transition effect recognized in beginning retained earnings as of the date of adoption. The impact of the implementation to the consolidated financial statements for periods subsequent to adoption is not material. See Note 4, "Revenue Recognition" for a discussion regarding revenue recognition under the new standard. In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The ASU was issued as part of the FASB Simplification Initiative and involves several aspects of accounting for share-based payment transactions, including the income tax consequences and classification on the statement of cash flows. We adopted this standard as of January 1, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows. In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230). The ASU provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The guidance addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. The ASU is effective for annual and interim periods beginning after December 15, 2017, which required the Company to adopt these provisions in the first quarter of fiscal 2018 using a retrospective approach. The adoption did not have a material impact on our financial position, results of operations or cash flows. In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which requires that the Statement of Cash Flows explain the changes during the period of cash and cash equivalents inclusive of amounts categorized as Restricted Cash. As a result, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for periods beginning after December 15, 2017, which required the Company to adopt these provisions in the first quarter of fiscal 2018. The adoption did not have a material impact on our financial position, results of operations or cash flows. In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805) - Clarifying the Definition of a Business, which provides guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The adoption is effective for annual and interim periods beginning after December 15, 2017. The Company will evaluate future acquisitions under this guidance, which may result in future acquisitions being accounted for as asset acquisitions. In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. The amended standard specifies the modification accounting applicable to any entity which changes the terms or conditions of a share-based payment award. The new guidance is effective for all entities after December 15, 2017. The adoption did not have a material impact on our financial position, results of operations or cash flows. Accounting Standards Recently Issued But Not Yet Adopted by the Company In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The standard establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. For short term leases (those with a term of 12 months or less and that do not include a lessee purchase option that is reasonably certain to be exercised), a lessee is permitted to make an accounting election by asset class not to recognize lease assets and lease liabilities, which would generally result in lease expense being recognized on a straight-line basis over the lease term. The standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. In July 2018, the FASB issued ASU 2018-11, Leases - Targeted Improvements, which allows lessees and lessors to recognize and measure existing leases at the beginning of the period of adoption without modifying the comparative period financial statements (which therefore will remain under prior GAAP, Topic 840, Leases). The Company intends to use the optional expedient to reflect adoption in the period of adoption (which is January 1, 2019 for us) rather than the earliest period presented. For periods presented under Topic 842, extensive quantitative and qualitative disclosures will be required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The Company anticipates this standard will have a material impact on the consolidated financial position, primarily from nursing center operating leases. The Company has organized an implementation group of cross-functional departmental management to ensure the completeness of the lease information (specifically for new contracts entered into after the adoption date), analyze the appropriate classification of leases under the new standard, and develop new processes to execute, approve and classify new leases on an ongoing basis. The Company has also implemented software tools and processes to maintain lease information critical to applying the standard. The Company is in the process of cataloging its existing lease contracts and implementing changes to the systems, related processes and controls. The Company is planning to elect the package of practical expedients upon transition, which includes retaining the lease classification for any leases that exist prior to adoption of the standard. The Company is continuing to evaluate the extent of this anticipated impact on the consolidated financial position and results of operations and the quantitative and qualitative factors that will impact the Company as part of the adoption. The Company is additionally evaluating any modifications to its leasing strategy in response to the requirements of this standard. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This update is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments that are not accounted for at fair value through net income, including loans held for investment, held-to-maturity debt securities, trade and other receivables, net investment in leases and other such commitments. This update requires that financial statement assets measured at an amortized cost be presented at the net amount expected to be collected, through an allowance for credit losses that is deducted from the amortized cost basis. This standard is effective for the fiscal year beginning after December 15, 2019 with early adoption permitted. The Company is in the initial stages of evaluating the impact from the adoption of this new standard on the consolidated financial statements and related notes. In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which is intended to simplify and amend the application of hedge accounting to more clearly portray the economics of an entity’s risk management strategies in its financial statements. The new guidance will make more financial and nonfinancial hedging strategies eligible for hedge accounting and reduce complexity in fair value hedges of interest rate risk. The new guidance also changes how companies assess effectiveness and amends the presentation and disclosure requirements. The new guidance eliminates the requirement to separately measure and report hedge ineffectiveness and generally the entire change in the fair value of a hedging instrument will be required to be presented in the same income statement line as the hedged item. The new guidance also eases certain documentation and assessment requirements and modifies the accounting for components excluded from the assessment of hedge effectiveness. The new guidance is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within those years. Early adoption is permitted in any interim period or fiscal year before the effective date. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures. In February 2018, the FASB issued ASU No. 2018-02, Income Statement- Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The new guidance allows entities the option to reclassify stranded tax effects resulting from the Tax Cuts and Jobs Act from accumulated other comprehensive income (OCI) to retained earnings. The new guidance allows the option to apply the guidance retrospectively or in the period of adoption. The guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company is evaluating the effect this guidance will have on our consolidated financial statements and related disclosures. In March 2018, the FASB issued ASU No. 2018-05, Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 ("SAB No. 118"), which allowed SEC registrants to record provisional amounts in earnings for the year ended December 31, 2017 due to the complexities involved in accounting for the enactment of the Tax Cuts and Jobs Act. The Company recognized the estimated income tax effects of the Tax Cuts and Jobs Act in its 2017 Consolidated Financial Statements in accordance with SAB No. 118.
Revenue Recognition	On January 1, 2018, the Company adopted Accounting Standards Codification ("ASC") 606 using the modified retrospective method for all contracts as of the date of adoption. The reported results for 2018 reflect the application of ASC 606 guidance while the reported results for 2017 were prepared under the guidance of ASC 605, Revenue Recognition (ASC 605), which is also referred to herein as "legacy GAAP". The adoption of ASC 606 represents a change in accounting principle that will more closely align revenue recognition with the delivery of the Company's services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these services. ASC 606 requires companies to exercise more judgment and recognize revenue in accordance with the standard's core principle by applying the following five steps: Step 1: Identify the contract with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. Performance obligations are promises made in a contract to transfer a distinct good or service to the customer. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company has concluded that the contracts with patients and residents represent a bundle of distinct services that are substantially the same, with the same pattern of transfer to the customer. Accordingly, the promise to provide quality care is accounted for as a single performance obligation. The Company performed analyses using the application of the portfolio approach as a practical expedient to group patient contracts with similar characteristics, such that revenue for a given portfolio would not be materially different than if it were evaluated on a contract-by-contract basis. These analyses incorporated consideration of reimbursements at varying rates from Medicaid, Medicare, Managed Care, Private Pay, Assisted Living, Hospice, and Veterans for services provided in each corresponding state. It was determined that the contracts are not materially different for the following groups: Medicaid, Medicare, Managed Care and Private Pay and other (Assisted Living, Hospice and Veterans). In order to determine the transaction price, the Company estimates the amount of variable consideration at the beginning of the contract using the expected value method. The estimates consider (i) payor type, (ii) historical payment trends, (iii) the maturity of the portfolio, and (iv) geographic payment trends throughout a class of similar payors. The Company typically enters into agreements with third-party payors that provide for payments at amounts different from the established charges. These arrangement terms provide for subsequent settlement and cash flows that may occur well after the service is provided. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. Changes in the Company's expectation of the amount it will receive from the patient or third-party payors will be recorded in revenue unless there is a specific event that suggests the patient or third-party payor no longer has the ability and intent to pay the amount due and, therefore, the changes in its estimate of variable consideration better represent an impairment, or bad debt. These estimates are re-assessed each reporting period, and any amounts allocated to a satisfied performance obligation are recognized as revenue or a reduction of revenue in the period in which the transaction price changes. The Company satisfies its performance obligation by providing quality of care services to its patients and residents on a daily basis until termination of the contract. The performance obligation is recognized on a time elapsed basis, by day, for which the services are provided. For these contracts, the Company has the right to consideration from the customer in an amount that directly corresponds with the value to the customer of the Company's performance to date. Therefore, the Company recognizes revenue based on the amount billable to the customer in accordance with the practical expedient in ASC 606-10-55-18. Additionally, because the Company applied ASC 606 using certain practical expedients, the Company elected not to disclose the aggregate amount of the transaction price for unsatisfied, or partially unsatisfied, performance obligations for all contracts with an original expected length of one year or less. The Company incurs costs related to patient/resident contracts, such as legal and advertising expenses. The contract costs are expensed as incurred. They are not expected to be recovered and are not chargeable to the patient/resident regardless of whether the contract is executed.

REVENUE RECOGNITION (Tables)

REVENUE RECOGNITION (Tables)	9 Months Ended
	Sep. 30, 2018
Revenue from Contract with Customer [Abstract]
Schedule of New Accounting Pronouncements and Changes in Accounting Principles	As a result of applying the modified retrospective method to adopt ASC 606, the following adjustments were made to our operating results: Three Months Ended September 30, 2018 As Reported Increase (Decrease) Balances as if the previous accounting guidance was in effect Patient Revenues, net $141,431 3,903 (a) $145,065 (269) (b) 3,634 Operating Expenses $113,799 3,903 (a) $117,702 Total Expenses $147,397 3,903 (a) $151,300 (a) Adjusts for the implicit price concession of bad debt expense. (b) Adjusts for the implementation of ASC 606. Nine Months Ended September 30, 2018 As Reported Increase (Decrease) Balances as if the previous accounting guidance was in effect Patient Revenues, net $423,798 11,155 (a) $434,066 (887) (b) 10,268 Operating Expenses $337,517 11,155 (a) $348,672 Total Expenses $427,672 11,155 (a) $438,827 (a) Adjusts for the implicit price concession of bad debt expense. (b) Adjusts for the implementation of ASC 606. As of September 30, 2018 As Reported Increase (Decrease) Balances as if the previous accounting guidance was in effect Accounts Receivable $65,927 (887) (a) $81,275 16,235 (b) 15,348 Accumulated Deficit $(23,432) 887 (a) $(22,829) (284) (c) 603 (a) Adjusts for the implementation of ASC 606. (b) Adjusts for a direct reduction of accounts receivable that would have been reflected as allowance for doubtful accounts in the consolidated balance sheet prior to the adoption of ASC 606. (c) Reflects the tax impact for the ASC 606 adjustment of $887 .
Disaggregation of Revenue	The following table summarizes revenue from contracts with customers by payor source for the periods presented (dollar amounts in thousands): Three Months Ended September 30, 2018 2018 2017(1) As reported As Adjusted to Legacy GAAP As reported Medicaid $ 68,929 48.7 % $ 78,200 53.9 % $ 77,027 52.6 % Medicare 26,997 19.1 % 34,933 24.1 % 36,449 24.9 % Managed Care 12,404 8.8 % 10,874 7.5 % 10,992 7.5 % Private Pay and other 33,101 23.4 % 21,058 14.5 % 21,909 15.0 % Total $ 141,431 100.0 % $ 145,065 100.0 % $ 146,377 100.0 % Nine Months Ended September 30, 2018 2018 2017(1) As reported As Adjusted to Legacy GAAP As reported Medicaid $ 198,418 46.8 % $ 226,631 52.2 % $ 223,410 51.9 % Medicare 84,611 20.0 % 109,150 25.1 % 113,360 26.3 % Managed Care 39,919 9.4 % 34,854 8.0 % 31,756 7.4 % Private Pay and other 100,850 23.8 % 63,431 14.7 % 61,901 14.4 % Total $ 423,798 100.0 % $ 434,066 100.0 % $ 430,427 100.0 % (1) As noted above, prior period amounts have not been adjusted under the application of the modified retrospective method.

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	9 Months Ended
	Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summarized activity of equity compensation plans	Summarized activity of the equity compensation plans is presented below: Weighted Options/ Average SOSARs Exercise Price Outstanding, December 31, 2017 211 $ 6.64 Granted 30 8.14 Exercised (100 ) 5.79 Expired or cancelled (17 ) 9.76 Outstanding, September 30, 2018 124 $ 7.24 Exercisable, September 30, 2018 104 $ 7.06
Schedule of summarized activity of Restricted Share Units	Weighted Average Restricted Grant Date Shares Fair Value Outstanding, December 31, 2017 164 $ 9.95 Granted 90 8.14 Dividend Equivalents 4 6.95 Vested (131 ) 9.71 Cancelled (7 ) 9.62 Outstanding, September 30, 2018 120 $ 8.77 Summarized activity of the Restricted Share Units for the Stock Purchase Plan is as follows: Weighted Average Restricted Grant Date Share Units Fair Value Outstanding, December 31, 2017 44 $ 9.59 Granted 16 8.14 Dividend Equivalents 1 6.89 Vested (17 ) 8.91 Outstanding, September 30, 2018 44 $ 9.25
Schedule of summarized information regarding stock options and SOSAR grants outstanding	The following table summarizes information regarding stock options and SOSAR grants outstanding as of September 30, 2018 : Weighted Average Intrinsic Intrinsic Range of Exercise Grants Value-Grants Grants Value-Grants Exercise Prices Prices Outstanding Outstanding Exercisable Exercisable $8.14 to $10.80 $ 9.32 60 $ — 40 $ — $2.37 to $5.86 $ 5.28 64 $ 75 64 $ 75 124 104

EARNINGS PER COMMON SHARE (Tabl

EARNINGS PER COMMON SHARE (Tables)	9 Months Ended
	Sep. 30, 2018
Earnings Per Share [Abstract]
Basic and diluted net income (loss) per common share	Information with respect to basic and diluted net income (loss) per common share is presented below in thousands, except per share: Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Net loss Income (loss) from continuing operations $ (7,389 ) $ (581 ) $ (7,777 ) $ 1,148 Income (loss) from discontinued operations, net of income taxes (8 ) 1 (34 ) (42 ) Net loss $ (7,397 ) $ (580 ) $ (7,811 ) $ 1,106 Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Net income (loss) per common share: Per common share – basic Income (loss) from continuing operations $ (1.15 ) $ (0.09 ) $ (1.22 ) $ 0.18 Loss from discontinued operations — — (0.01 ) (0.01 ) Net income (loss) per common share – basic $ (1.15 ) $ (0.09 ) $ (1.23 ) $ 0.17 Per common share – diluted Income (loss) from continuing operations $ (1.15 ) $ (0.09 ) $ (1.22 ) $ 0.18 Loss from discontinued operations — — (0.01 ) (0.01 ) Net income (loss) per common share – diluted $ (1.15 ) $ (0.09 ) $ (1.23 ) $ 0.17 Weighted Average Common Shares Outstanding: Basic 6,400 6,294 6,362 6,274 Diluted 6,400 6,294 6,362 6,465

BUSINESS DEVELOPMENTS AND OTH_2

BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS (Tables)	9 Months Ended
	Sep. 30, 2018
Business Combinations [Abstract]
Schedule of allocation for net assets acquired	The final allocation of the purchase price to the net assets acquired is as follows: Park Place Purchase Price $ 8,750 Gain on bargain purchase 925 $ 9,675 Allocation: Building $ 8,435 Land 760 Land Improvements 145 Furniture, Fixtures and Equipment 335 $ 9,675

BUSINESS (Details)

BUSINESS (Details)	Sep. 30, 2018statecenterbed
Accounting Policies [Line Items]
Number of states in which entity operates | state	10
Number of nursing centers | center	76
Number of licensed nursing beds	8,456
Number of nursing center facilities owned | center	18
Number of nursing center facilities leased | center	58
Number of licensed assisted and residential living beds	497
Minimum
Accounting Policies [Line Items]
Number of licensed nursing beds per center	48
Maximum
Accounting Policies [Line Items]
Number of licensed nursing beds per center	320

CONSOLIDATION AND BASIS OF PR_3

CONSOLIDATION AND BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Details) $ in Thousands	3 Months Ended	9 Months Ended
	Dec. 31, 2016USD ($)investment	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)
Schedule of Equity Method Investments [Line Items]
Number of equity method investments sold | investment	1
Gain on sale of investment in unconsolidated affiliate		$ 308	$ 733
Unnamed pharmacy joint venture
Schedule of Equity Method Investments [Line Items]
Gain on sale of investment in unconsolidated affiliate	$ 1,366	$ 308	$ 733

REVENUE RECOGNITION - Adjustme

REVENUE RECOGNITION - Adjustments to Operating Results (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Patient Revenues, net	$ 141,431	$ 146,377	$ 423,798	$ 430,427
Operating Expenses	113,799	118,104	337,517	341,937
Total Expenses	147,397	$ 145,403	427,672	$ 424,437
Accounts Receivable	65,927		65,927		$ 64,929
Accumulated Deficit	(23,432)		(23,432)		$ (14,534)
Difference Between Revenue Guidance In Effect before And After Topic 606, Adjustment For Implicit Price Concession Of Bad Debt Expense | Accounting Standards Update 2014-09
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Patient Revenues, net	3,903		11,155
Difference Between Revenue Guidance In Effect before And After Topic 606, Adjustment For Implementation | Accounting Standards Update 2014-09
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Patient Revenues, net	(269)		(887)
Accounts Receivable	(887)		(887)
Accumulated Deficit	887		887
Difference Between Revenue Guidance In Effect before And After Topic 606, Allowance For Doubtful Accounts | Accounting Standards Update 2014-09
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Accounts Receivable	16,235		16,235
Difference Between Revenue Guidance In Effect before And After Topic 606, Tax Adjustment | Accounting Standards Update 2014-09
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Accumulated Deficit	(284)		(284)
Difference between Revenue Guidance in Effect before and after Topic 606 | Accounting Standards Update 2014-09
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Patient Revenues, net	3,634		10,268
Operating Expenses	3,903		11,155
Total Expenses	3,903		11,155
Accounts Receivable	15,348		15,348
Accumulated Deficit	603		603
Calculated under Revenue Guidance in Effect before Topic 606
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Patient Revenues, net	145,065		434,066
Operating Expenses	117,702		348,672
Total Expenses	151,300		438,827
Accounts Receivable	81,275		81,275
Accumulated Deficit	$ (22,829)		$ (22,829)

REVENUE RECOGNITION - Disaggre

REVENUE RECOGNITION - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Disaggregation of Revenue [Line Items]
Total revenues	$ 141,431		$ 423,798
Total revenues, as a percent	100.00%		100.00%
Medicaid
Disaggregation of Revenue [Line Items]
Total revenues	$ 68,929		$ 198,418
Total revenues, as a percent	48.70%		46.80%
Medicare
Disaggregation of Revenue [Line Items]
Total revenues	$ 26,997		$ 84,611
Total revenues, as a percent	19.10%		20.00%
Managed Care
Disaggregation of Revenue [Line Items]
Total revenues	$ 12,404		$ 39,919
Total revenues, as a percent	8.80%		9.40%
Private Pay and other
Disaggregation of Revenue [Line Items]
Total revenues	$ 33,101		$ 100,850
Total revenues, as a percent	23.40%		23.80%
Calculated under Revenue Guidance in Effect before Topic 606
Disaggregation of Revenue [Line Items]
Total revenues	$ 145,065	$ 146,377	$ 434,066	$ 430,427
Total revenues, as a percent	100.00%	100.00%	100.00%	100.00%
Calculated under Revenue Guidance in Effect before Topic 606 | Medicaid
Disaggregation of Revenue [Line Items]
Total revenues	$ 78,200	$ 77,027	$ 226,631	$ 223,410
Total revenues, as a percent	53.90%	52.60%	52.20%	51.90%
Calculated under Revenue Guidance in Effect before Topic 606 | Medicare
Disaggregation of Revenue [Line Items]
Total revenues	$ 34,933	$ 36,449	$ 109,150	$ 113,360
Total revenues, as a percent	24.10%	24.90%	25.10%	26.30%
Calculated under Revenue Guidance in Effect before Topic 606 | Managed Care
Disaggregation of Revenue [Line Items]
Total revenues	$ 10,874	$ 10,992	$ 34,854	$ 31,756
Total revenues, as a percent	7.50%	7.50%	8.00%	7.40%
Calculated under Revenue Guidance in Effect before Topic 606 | Private Pay and other
Disaggregation of Revenue [Line Items]
Total revenues	$ 21,058	$ 21,909	$ 63,431	$ 61,901
Total revenues, as a percent	14.50%	15.00%	14.70%	14.40%

LONG-TERM DEBT AND INTEREST R_2

LONG-TERM DEBT AND INTEREST RATE SWAP (Details)	Feb. 26, 2016USD ($)center	Sep. 30, 2018USD ($)letter_of_credit	Mar. 31, 2018	Sep. 30, 2017USD ($)	Sep. 30, 2018USD ($)letter_of_credit	Sep. 30, 2017USD ($)	Dec. 31, 2017USD ($)	Aug. 01, 2017USD ($)	Jun. 30, 2017USD ($)	Dec. 29, 2016USD ($)	Dec. 28, 2016USD ($)	Oct. 03, 2016USD ($)
Line of Credit Facility [Line Items]
Accumulated other comprehensive income (loss)		$ 1,059,000			$ 1,059,000		$ 709,000
Income tax benefit, interest rate swap		(207,000)		$ (345,000)	(670,000)	$ 651,000
Interest rate swap
Line of Credit Facility [Line Items]
Notional amount of interest rate derivatives		$ 27,915,000			$ 27,915,000
Annual fixed rate percentage		5.79%			5.79%
Net asset based on interest rate swap valuation model		$ 661,000			$ 661,000
Accumulated other comprehensive income (loss)		$ 403,000			403,000
Income tax benefit, interest rate swap					$ 258,000
Amended and restated credit agreement
Line of Credit Facility [Line Items]
Loan acquisition costs	$ 2,162,000
Number of letters of credit | letter_of_credit		11			11
Credit agreement | Amended and restated credit agreement
Line of Credit Facility [Line Items]
Borrowing capacity	$ 100,000,000
Term of agreements	5 years
Mortgage loan | Amended and restated credit agreement
Line of Credit Facility [Line Items]
Borrowing capacity	$ 72,500,000
Term of agreements	5 years
Period of amortization	25 years
Amended mortgage loan balance		$ 72,150,000			$ 72,150,000
Number of owned nursing centers to secure Amended Mortgage Loan | center	18
Mortgage loan | Amended and restated credit agreement | Interest rate swap
Line of Credit Facility [Line Items]
Debt interest rate at period end	5.79%
Amended revolver | Amended and restated credit agreement
Line of Credit Facility [Line Items]
Borrowing capacity	$ 27,500,000	37,710,000			37,710,000			$ 42,250,000	$ 52,250,000			$ 52,250,000
Fixed charge coverage ratio			1.01
Borrowings outstanding		18,500,000			$ 18,500,000		$ 16,000,000
Interest rate during period					6.00%
Balance available for borrowing under revolving credit center		$ 5,496,000			$ 5,496,000
Amended revolver | Amended and restated credit agreement | LIBOR
Line of Credit Facility [Line Items]
Interest rate percentage	4.00%
Letter of credit | Amended and restated credit agreement
Line of Credit Facility [Line Items]
Borrowing capacity										$ 15,000,000	$ 10,000,000
Annual fees for letters of credit issued under Revolver (as a percentage)	3.00%
Mortgage term loan | Mortgage loan | Amended and restated credit agreement
Line of Credit Facility [Line Items]
Borrowing capacity	$ 60,000,000
Debt interest rate at period end		6.00%			6.00%
Amended mortgage loan balance		$ 63,150,000			$ 63,150,000
Increase to credit facility limit									$ 7,500,000
Mortgage term loan | Mortgage loan | Amended and restated credit agreement | Interest rate swap | Designated as hedging instrument
Line of Credit Facility [Line Items]
Notional amount of interest rate derivatives	$ 30,000,000
Mortgage term loan | Mortgage loan | Amended and restated credit agreement | LIBOR
Line of Credit Facility [Line Items]
Interest rate percentage	4.00%
Acquisition loan facility | Mortgage loan | Amended and restated credit agreement
Line of Credit Facility [Line Items]
Borrowing capacity	$ 12,500,000
Debt interest rate at period end		6.80%			6.80%
Amended mortgage loan balance		$ 9,000,000			$ 9,000,000
Acquisition loan facility | Mortgage loan | Amended and restated credit agreement | LIBOR
Line of Credit Facility [Line Items]
Interest rate percentage	4.75%
Omega Healthcare Investors Inc | Amended revolver | Amended and restated credit agreement
Line of Credit Facility [Line Items]
Letters of credit security deposit for a lease		$ 13,714,000			$ 13,714,000

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details)	9 Months Ended		32 Months Ended
	Sep. 30, 2018USD ($)lawsuit	Sep. 30, 2017USD ($)	Feb. 29, 2016civil_investigative_demand	Dec. 31, 2017USD ($)	Oct. 31, 2014facility
Malpractice Insurance [Line Items]
Number of professional liability lawsuits | lawsuit	83
Cash expenditures for self-insured professional liability costs	$ 4,452,000	$ 6,077,000
Estimated insurance recovery receivables	5,425,000
Accrued litigation contingency	6,400,000			$ 0
Other Insurance
Liability for workers compensation claims	620,000
Workers compensation insurance, non current receivable for excess premiums paid	1,074,000
Unfavorable regulatory action | Potential violations of false claims act
Malpractice Insurance [Line Items]
Number of facilities | facility					2
Number of civil investigative demands received | civil_investigative_demand			3
Professional malpractice liability insurance
Malpractice Insurance [Line Items]
Liability for reported and estimated future claims	27,070,000
Prefunded deductible policy
Malpractice Insurance [Line Items]
Insurance policy coverage limits per claim	500,000
Other Insurance
Insurance policy coverage limits per claim	500,000
Professional liability insurance, annual coverage limit per facility	3,000,000
Health insurance, maximum self-insured annual amount per individual	200,000
Liability for reported claims and estimates for incurred but unreported claims	1,662,000
SHC Risk Carriers, Inc | Professional malpractice liability insurance
Malpractice Insurance [Line Items]
Insurance policy coverage limits per claim	500,000
Malpractice insurance annual sublimit per center	1,000,000
Aggregate policy limit	5,000,000
Other Insurance
Insurance policy coverage limits per claim	$ 500,000
Scheduled for trial or arbitration over next 12 months
Malpractice Insurance [Line Items]
Number of professional liability lawsuits | lawsuit	20

STOCK-BASED COMPENSATION - Nar

STOCK-BASED COMPENSATION - Narrative (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2018USD ($)directorshares	Sep. 30, 2017USD ($)shares	May 31, 2017shares	Jun. 30, 2016shares	May 31, 2016shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of new directors who received options | director	2
Share-based compensation expense | $	$ 947	$ 766
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant of restricted common stock (shares)	90,000	88,000
Restricted Stock | First anniversary of grant date
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage of awards	33.00%
Restricted Stock | Second anniversary of grant date
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage of awards	33.00%
Restricted Stock | Third anniversary of grant date
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage of awards	33.00%
Stock Options and Stock Appreciation Rights (SARs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Payment award, expiration period	10 years
Stock Options and Stock Appreciation Rights (SARs) | First anniversary of grant date
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage of awards	33.00%
Stock Options and Stock Appreciation Rights (SARs) | Second anniversary of grant date
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage of awards	33.00%
Stock Options and Stock Appreciation Rights (SARs) | Third anniversary of grant date
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage of awards	33.00%
Executive Equity Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense | $	$ 259
2008 Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of quoted market price offering rate	85.00%
Restriction period	2 years
Shares authorized under the plan (shares)				350,000	150,000
2010 Long Term Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance (shares)		680,000	380,000
Director | Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage of awards	33.33%
Stock options granted (in shares)	30,000
Director | Stock Option | First anniversary of grant date
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage of awards	33.33%
Director | Stock Option | Second anniversary of grant date
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage of awards	33.33%

STOCK-BASED COMPENSATION - Sch

STOCK-BASED COMPENSATION - Schedule of Activity of Equity Compensation Plans (Details) - Stock Options and Stock Appreciation Rights (SARs) shares in Thousands	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Number of Shares
Outstanding, beginning (shares) | shares	211
Granted (shares) | shares	30
Exercised (shares) | shares	(100)
Expired or cancelled (shares) | shares	(17)
Outstanding, ending (shares) | shares	124
Exercisable (shares) | shares	104
Weighted Average Exercise Price
Outstanding, beginning (dollars per share) | $ / shares	$ 6.64
Granted (dollars per share) | $ / shares	8.14
Exercised (dollars per share) | $ / shares	5.79
Expired or cancelled (dollars per share) | $ / shares	9.76
Outstanding, ending (dollars per share) | $ / shares	7.24
Exercisable, weighted average exercise price (dollars per share) | $ / shares	$ 7.06

STOCK-BASED COMPENSATION - S_2

STOCK-BASED COMPENSATION - Schedule of Restricted Stock and Restricted Stock Units Activity (Details) shares in Thousands	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Restricted Stock Units (RSUs)
Number of Shares
Outstanding, beginning (share) | shares	164
Granted (shares) | shares	90
Dividend Equivalents (shares) | shares	4
Vested (shares) | shares	(131)
Cancelled (shares) | shares	(7)
Outstanding, ending (shares) | shares	120
Weighted Average Granted Date Fair Value
Outstanding, beginning (dollars per share) | $ / shares	$ 9.95
Granted (dollars per share) | $ / shares	8.14
Dividend Equivalents (dollars per share) | $ / shares	6.95
Vested (dollars per share) | $ / shares	9.71
Cancelled (dollars per share) | $ / shares	9.62
Outstanding, ending (dollars per share) | $ / shares	$ 8.77
Employee Stock
Number of Shares
Outstanding, beginning (share) | shares	44
Granted (shares) | shares	16
Dividend Equivalents (shares) | shares	1
Vested (shares) | shares	(17)
Outstanding, ending (shares) | shares	44
Weighted Average Granted Date Fair Value
Outstanding, beginning (dollars per share) | $ / shares	$ 9.59
Granted (dollars per share) | $ / shares	8.14
Dividend Equivalents (dollars per share) | $ / shares	6.89
Vested (dollars per share) | $ / shares	8.91
Outstanding, ending (dollars per share) | $ / shares	$ 9.25

STOCK-BASED COMPENSATION - S_3

STOCK-BASED COMPENSATION - Schedule of Awards Outstanding and Exercisable (Details) - Stock Options and Stock Appreciation Rights (SARs) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise prices (dollars per share)	$ 7.24	$ 6.64
Grants outstanding (shares)	124
Grants exercisable (shares)	104
$8.14 to $10.80
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices, minimum (dollars per share)	$ 8.14
Range of exercise prices, maximum (dollars per share)	10.80
Weighted average exercise prices (dollars per share)	$ 9.32
Grants outstanding (shares)	60
Intrinsic value - grants outstanding	$ 0
Grants exercisable (shares)	40
Intrinsic value - grants exercisable	$ 0
$2.37 to $5.86
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices, minimum (dollars per share)	$ 2.37
Range of exercise prices, maximum (dollars per share)	5.86
Weighted average exercise prices (dollars per share)	$ 5.28
Grants outstanding (shares)	64
Intrinsic value - grants outstanding	$ 75
Grants exercisable (shares)	64
Intrinsic value - grants exercisable	$ 75

EARNINGS PER COMMON SHARE - Ba

EARNINGS PER COMMON SHARE - Basic and Diluted Net Income (Loss) Per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Net loss
Income (loss) from continuing operations	$ (7,389)	$ (581)	$ (7,777)	$ 1,148
Income (loss) from discontinued operations, net of income taxes	(8)	1	(34)	(42)
Net loss	$ (7,397)	$ (580)	$ (7,811)	$ 1,106
Per common share – basic
Income (loss) from continuing operations (dollars per share)	$ (1.15)	$ (0.09)	$ (1.22)	$ 0.18
Loss from discontinued operations (dollars per share)	0	0	(0.01)	(0.01)
Net income (loss) per common share – basic (dollars per share)	(1.15)	(0.09)	(1.23)	0.17
Per common share – diluted
Income (loss) from continuing operations (dollars per share)	(1.15)	(0.09)	(1.22)	0.18
Loss from discontinued operations (dollars per share)	0	0	(0.01)	(0.01)
Net income (loss) per common share – diluted (dollars per share)	$ (1.15)	$ (0.09)	$ (1.23)	$ 0.17
Weighted Average Common Shares Outstanding:
Basic (shares)	6,400	6,294	6,362	6,274
Diluted (shares)	6,400	6,294	6,362	6,465

EARNINGS PER COMMON SHARE - Na

EARNINGS PER COMMON SHARE - Narrative (Details) - shares shares in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Earnings Per Share [Abstract]
Antidilutive shares excluded from computation of diluted earnings per share (shares)	124	46

BUSINESS DEVELOPMENTS AND OTH_3

BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS - Narrative (Details) $ in Thousands	Jul. 01, 2017USD ($)bed	Sep. 30, 2018USD ($)bed	Mar. 31, 2018facility	Sep. 30, 2017USD ($)	Dec. 31, 2016USD ($)	Sep. 30, 2018USD ($)bed	Sep. 30, 2017USD ($)	Dec. 31, 2017USD ($)
Business Acquisition [Line Items]
Number of licensed nursing beds | bed		8,456				8,456
Number of skilled nursing facilities classified as held for sale | facility			3
Assets held for sale		$ 13,299				$ 13,299		$ 0
Cash termination payment		$ 13,764		$ 13,791		41,202	$ 41,297
Gain on sale of investment in unconsolidated affiliate						308	733
Selma Nursing Centers
Business Acquisition [Line Items]
Number of licensed nursing beds | bed	103
Purchase Price	$ 8,750
Business acquisition, acquisition expenses								140
Gain on bargain purchase	$ 925							925
Unnamed pharmacy joint venture
Business Acquisition [Line Items]
Gain on sale of investment in unconsolidated affiliate					$ 1,366	$ 308	$ 733
Trend Health and Rehab of Carthage, LLC (Trend Health)
Business Acquisition [Line Items]
Cash termination payment								$ 250

BUSINESS DEVELOPMENTS AND OTH_4

BUSINESS DEVELOPMENTS AND OTHER SIGNIFICANT TRANSACTIONS - Schedule of Assets Acquired (Details) - Selma Nursing Centers - USD ($) $ in Thousands	Jul. 01, 2017	Dec. 31, 2017
Business Acquisition [Line Items]
Purchase Price	$ 8,750
Gain on bargain purchase	925	$ 925
Assets acquired	9,675
Building	8,435
Land	760
Land Improvements	145
Furniture, Fixtures and Equipment	$ 335

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) $ in Thousands	Oct. 30, 2018USD ($)	Oct. 01, 2018extensioncenter	Sep. 30, 2018center
Subsequent Event [Line Items]
Number of nursing center facilities leased			58
Subsequent Event
Subsequent Event [Line Items]
Number of nursing center facilities leased		34
Number of skilled nursing centers under lease		23
Operating lease, initial term		12 years
Number of lease extensions allowed | extension		2
Lease extension period		10 years
Annual lease fixed escalators, percent		2.15%
Omega Healthcare Investors Inc | Subsequent Event
Subsequent Event [Line Items]
Number of nursing center facilities leased		11
The Properties | Disposal Group, Disposed of by Sale, Not Discontinued Operations | Subsequent Event
Subsequent Event [Line Items]
Proceeds from divestiture of businesses | $	$ 18,700